An increased incidence of Hodgkin's lymphoma in patients with adult-onset sarcoma

Table 2 Hodgkin's lymphoma and sarcoma in 8 probands

Case	Gender	HL age onset	HL subtype	HL site	HL treatment		Other primary malignancy	Sarcoma age onset	HL - Sarcoma Latency (years)	Sarcoma subtype	Sarcoma site	Relation to HL RT
					CT	RT
1	M	52	Nodular sclerosing	Neck	ABVD 4 cycles	MFRT 30.6 Gy 17#	Melanoma L UL 59 y excision	61	9	Fibromyxosarcoma	R thigh	Not in field
2	M	44	Nodular sclerosing	Head/neck	NM 6 cycles	35 Gy 20#	-	69	25	Fibromyxosarcoma	R UL	In field
3*	M	34	Mixed cellularity	R axilla	MOPP + ABVD 8 cycles combination	MRFT 38 Gy 27#	Melanoma UL 47 y excision	60	26	Pleomorphic cell sarcoma NOS	L latissimus dorsi	In field
4	M	51	Nodular sclerosing	Chest	ABVD	IFRT dose unknown	-	62	11	Leiomyosarcoma	Pelvis	Not in field
5	F	33	Unknown	L axilla	CT treatment records unavailable	RT dose unknown	-	52	19	Osteosarcoma	L latissimus dorsi	In field
6	M	19	Nodular sclerosing	Chest, lungs	ABVD 1 cycle	-	-	19	0	Chondroblastic osteosarcoma	R LL	No RT Synchronous diagnoses
7	F	18	Nodular sclerosing	Chest, abdomen, pelvis	CT	-	-	27	9	Clear cell sarcoma	Small bowel	No RT
8	M	22	Mixed cellularity	Neck, chest, abdomen	CT	36 Gy 18#	-	54	32	Malignant fibrous histiocytoma	L thigh	Not in field

* TP53 mutation positive
ABVD Adriamycin, bleomycin, vinblastine, dacarbazine, CT chemotherapy, F female, Gy gray, IFRT Involved field radiotherapy, HL Hodgkin's lymphoma, L left, LL lower limb, M male, MFRT mantle field radiotherapy, MOPP Mustargen, Oncovin, Procarbazine, Prednisone, NM Nitrogen mustard, NOS not otherwise specified, RT radiotherapy, R right, UL upper limb

ISSN: 2045-3329